What is Dermatomyositis?
Dermatomyositis (DM) is a systemic autoimmune inflammatory myopathy characterised by two cardinal features: proximal skeletal muscle weakness and distinctive cutaneous (skin) manifestations. It belongs to the broader family of Idiopathic Inflammatory Myopathies (IIM), which also includes Polymyositis, Inclusion Body Myositis, and Anti-Synthetase Syndrome.
DM can affect adults (adult DM) and children (juvenile DM, which has a better prognosis). A critical concept is Clinically Amyopathic Dermatomyositis (CADM) — where patients have the characteristic skin features of DM but minimal or no muscle weakness, yet can develop the most severe form of interstitial lung disease (particularly associated with anti-MDA5 antibodies), causing rapidly progressive, often fatal respiratory failure.
Gottron's papules over the metacarpophalangeal joints — the most pathognomonic cutaneous finding in Dermatomyositis.
Characteristic Skin Manifestations
The skin findings of DM are so characteristic that their presence should immediately raise suspicion for this diagnosis:
- Gottron's Papules: Violaceous, scaly papules over the extensor surfaces of the metacarpophalangeal and interphalangeal joints. Pathognomonic for DM.
- Gottron's Sign: Erythema (redness) over the extensor surfaces of knuckles, elbows, and knees without papule formation.
- Heliotrope Rash: A distinctive violaceous discolouration of the eyelids, often with periorbital oedema — the purple "heliotrope" colour is characteristic.
- Shawl Sign: Erythema over the neck, shoulders, and upper back in a shawl distribution.
- V-Sign: Erythema in the V-area of the anterior neck and chest.
- Mechanic's Hands: Roughened, cracked, and hyperpigmented skin on the lateral and palmar surfaces of the fingers, particularly associated with Anti-Synthetase Syndrome (anti-Jo-1 antibodies).
- Periungual Telangiectasias: Dilated, tortuous blood vessels at the base of the nails — an important clinical sign also seen in other connective tissue diseases.
Clinical assessment of proximal muscle strength is essential in all patients with Dermatomyositis or Polymyositis.
🎗️ Cancer Association
Adult-onset Dermatomyositis is associated with an increased risk of cancer — particularly ovarian, lung, breast, colorectal, and nasopharyngeal cancer. All adult DM patients require comprehensive cancer screening at diagnosis and during follow-up, especially in the first 3-5 years. The presence of TIF1-γ antibodies is particularly strongly associated with malignancy.
Dr. Prateek's Approach to Dermatomyositis
Dermatomyositis requires expertise in myositis-specific antibody interpretation, ILD management, and cancer surveillance. Dr. Prateek Deo has the specialised knowledge and clinical experience to navigate all these complexities.
MSA Panel Testing
We use comprehensive myositis-specific and myositis-associated antibody (MSA/MAA) panels to predict ILD risk, cancer association, and treatment response, enabling truly personalised therapy.
ILD Monitoring
All DM patients receive baseline HRCT chest and pulmonary function tests, with surveillance for the rapidly progressive ILD especially associated with anti-MDA5 antibodies.
Cancer Screening
Systematic malignancy screening at diagnosis with CT chest/abdomen/pelvis and appropriate tumour markers, with annual surveillance thereafter.
Combination Immunosuppression
High-dose steroids combined with steroid-sparing agents (Azathioprine, Mycophenolate, or IVIG for refractory disease) and Rituximab for severe or refractory cases.